SCHEMBL12713217

SCHEMBL12713217

CCC(Cc1cc(Cl)ccc1C1CCN(C(=O)OC(C)(C)C)CC1)CN1CC[C@@H](F)C1

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ CNR1 P21554 3/20 0.42
▸ SMN1; SMN2 Q16637 2/20 0.42
▸ TP53 P04637 2/20 0.41
▸ POLB P06746 1/20 0.41
▸ DPP4 P27487 1/20 0.41
▸ UTS2R Q9UKP6 3/20 0.40
▸ MEN1 O00255 2/20 0.40
▸ KMT2A Q03164 2/20 0.40
▸ NPSR1 Q6W5P4 2/20 0.40
▸ GPR119 Q8TDV5 1/20 0.40
▸ ALDH1A1 P00352 1/20 0.40
▸ LMNA P02545 1/20 0.40
▸ GAA P10253 1/20 0.40
▸ STS P08842 1/20 0.40
▸ MC4R P32245 2/20 0.39
▸ USP2 O75604 1/20 0.39
▸ HPGD P15428 1/20 0.39
▸ HSD17B10 Q99714 1/20 0.39
▸ MAPT P10636 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13002965 0.90 SMN1; SMN2 (0.44) CNR1SMN1; SMN2TP53POLBDPP4
SCHEMBL12713213 0.86 SMN1; SMN2 (0.47) CNR1SMN1; SMN2TP53POLBDPP4
SCHEMBL14435613 0.82 DPP4 (0.44) DPP4MC4R
SCHEMBL12713214 0.79 SMN1; SMN2 (0.46) CNR1SMN1; SMN2TP53POLBDPP4
SCHEMBL12713212 0.79 TP53 (0.47) CNR1SMN1; SMN2TP53POLBDPP4
SCHEMBL12713199 0.79 SMN1; SMN2 (0.45) CNR1SMN1; SMN2TP53POLBUTS2R
SCHEMBL13948350 0.78 SMN1; SMN2 (0.45) CNR1SMN1; SMN2TP53POLBDPP4
SCHEMBL14436423 0.77 SMN1; SMN2 (0.47) CNR1SMN1; SMN2TP53POLBDPP4
SCHEMBL14401276 0.77 SMN1; SMN2 (0.47) CNR1SMN1; SMN2TP53POLBUTS2R
SCHEMBL12713228 0.77 GPR119 (0.51) CNR1SMN1; SMN2DPP4MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110086836-A1 Substituted Phenylpiperidine Derivatives As Melanocortin-4 Receptor Modulators SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) 2011-04-14 — — US disclosed
US-20110086836-A1 Substituted Phenylpiperidine Derivatives As Melanocortin-4 Receptor Modulators SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) 2011-04-14 — — US disclosed
WO-2007115798-A1 SUBSTITUTED PHENYLPIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) 2007-10-18 — — WO disclosed
WO-2007096186-A1 SUBSTITUTED PHENYLPIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) 2007-08-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110086836-A1 Substituted Phenylpiperidine Derivatives As Melanocortin-4 Receptor Modulators MC4R, MC5R, MC3R CNR1 238/4885SMN1; SMN2 1344/4885TP53 3292/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback